Validity of claims-based definitions of left ventricular systolic dysfunction in Medicare patients

Pharmacoepidemiology and Drug Safety

Volumn 20, Issue 7, 2011, Pages 700-708

  Li, Qian ^a   Glynn, Robert J ^b   Dreyer, Nancy A ^c   Liu, Jun ^b   Mogun, Helen ^b   Setoguchi, Soko ^b  

^a HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

^c Outcome Sciences Inc   (United States)

Author keywords

Bias; Claims based definition; Medicare claims; Specificity; Systolic dysfunction

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LOOP DIURETIC AGENT; NITRATE; RECEPTOR BLOCKING AGENT; SPIRONOLACTONE; STATIN; WARFARIN;

AGED; ARTICLE; DEFIBRILLATOR; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE REGISTRY; FEMALE; GOLD STANDARD; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL PATIENT; HOSPITALIZATION; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; OUTPATIENT; PHARMACY; PREDICTIVE VALIDITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SYSTOLIC DYSFUNCTION; SYSTOLIC HEART FAILURE;

AGED; AGED, 80 AND OVER; BIAS (EPIDEMIOLOGY); CARDIOVASCULAR AGENTS; CONFOUNDING FACTORS (EPIDEMIOLOGY); DATABASES, FACTUAL; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; INSURANCE CLAIM REVIEW; INTERNATIONAL CLASSIFICATION OF DISEASES; MALE; MEDICARE; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; STROKE VOLUME; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 79959721713     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2146     Document Type: Article

References (32)

1. Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006; 355: 260-269.
2. Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002; 346: 877-883.
3. Schneeweiss S, Avorn J. A review of uses of health care utilization databases for epidemiologic research on therapeutics. J Clin Epidemiol 2005; 58: 323-337.
4. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 1999; 353: 2001-2007.
5. Packer M, Coats AJ, Fowler MB, et al. Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 2001; 344: 1651-1658.
6. The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med 1991; 325: 293-302.
7. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med 1987; 316: 1429-1435.
8. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med 1991; 325: 303-310.
9. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717.
10. Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309-1321.
11. Hunt SA, Abraham WT, Chin MH, et al. 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009; 119: e391-e479.
12. Chavey II WE, Blaum CS, Bleske BE, et al. Guideline for the management of heart failure caused by systolic dysfunction: part II. Treatment. Am Fam Physician 2001; 64: 1045-1054.
13. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
14. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist and heart failure in elderly patients with rheumatoid arthritis. Am Heart J 2008; 156: 336-341.
15. LaBresh KA, Ellrodt AG, Gliklich R, et al. Get with the guidelines for cardiovascular secondary prevention: pilot results. Arch Intern Med 2004; 164: 203-209.
16. Hammill BG, Hernandez AF, Peterson ED, et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 2009; 157: 995-1000.
17. Yamamoto K, Burnett JC, Jr., Bermudez EA, et al. Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 2000; 6: 194-200.
18. Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation 2006; 114: 135-142.
19. Solomon SD, Anavekar N, Skali H, et al. Influence of ejection fraction on cardiovascular outcomes in a broad spectrum of heart failure patients. Circulation 2005; 112: 3738-3744.
20. Curtis LH, Al-Khatib SM, Shea AM, et al. Sex differences in the use of implantable cardioverter-defibrillators for primary and secondary prevention of sudden cardiac death. JAMA 2007; 298: 1517-1524.
21. Lee DS, Tu JV, Austin PC, et al. Effect of cardiac and noncardiac conditions on survival after defibrillator implantation. J Am Coll Cardiol 2007; 49: 2408-2415.
22. Setoguchi S, Shrank WH, Liu J, et al. Challenges in comparing effectiveness of angiotensin receptor blockers vs. angiotensin-converting enzyme inhibitors for hypertension in Medicare data. Clin Pharmacol Ther 2011; in press.
23. Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J 2008; 29: 2388-2442.
24. Savitz DA, Baron AE. Estimating and correcting for confounder misclassification. Am J Epidemiol 1989; 129: 1062-1071.
25. Schneeweiss S. Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics. Pharmacoepidemiol Drug Saf 2006; 15: 291-303.
26. Quach S, Blais C, Quan H. Administrative data have high variation in validity for recording heart failure. Can J Cardiol 2010; 26(8): 306-312.
27. Piot O. Atrial fibrillation and heart failure: a dangerous criminal conspiracy (French). Ann Cardiol Angeiol Paris 2009; 58 Suppl 1: S14-S16.
28. The BEST Investigators. A trial of the β-adrenergic blocker bucindolol in patients with advanced chronic heart failure. N Engl J Med 2001; 344: 1659-1667.
29. McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-added trial. Lancet 2003; 362: 767-771.
30. Gheorghiade M, Konstam MA, Burnett Jr JC, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007; 297: 1332-1343.
31. Setoguchi S, Glynn RJ, Avorn J, et al. Improvements in long-term mortality after myocardial infarction and increased use of cardiovascular drugs after discharge: a 10-year trend analysis. J Am Coll Cardiol 2008; 51: 1247-1254.
32. Setoguchi S, Levin R, Winkelmayer WC. Long-term trends of angiotensin-converting enzyme inhibitor and angiotensin-receptor blocker use after heart failure hospitalization in community-dwelling seniors. Int J Cardiol 2008; 125: 172-177.